The outpatient clinics market is projected to expand at a compound annual growth rate (CAGR) of 8% over the forecast period.

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusionAstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) ...

The breast lesion localization devices market is showing consistent expansion, with an estimated compound annual growth rate of approximately 7% over the forecast period. This growth is fueled by the ...

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering ·         Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM London, UK and Chicago, ...

MSF: Ethiopia’s first R21 malaria vaccine rollout, a global first in a refugee camp Addis Ababa – 15 December 2025: Médecins Sans Frontières (MSF) has completed the first full round of R21 malaria ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001.

German specialist in mixing, dispersing and powder-wetting technologies, is significantly strengthening its operations in India with the opening of a new facility in Bangalore. The expansion, which ...

Fida Biosystems welcomes Swedish Fåhraeus Startup and Growth Fund (FSG) as a new investor, while EIFO strengthens its commitment to the Danish innovator.Fida Biosystems, a Danish life science tools ...

OverviewThe global advanced wound closure market is expected to expand at a steady growth rate of around 6% over the next five years. This momentum is largely fueled by rising surgical volumes across ...

Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD ...

Global Dental Collagen Membranes Market OverviewThe global dental collagen membranes market is poised for strong expansion, projected to grow at a rate of approximately 9% over the next five years.

Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that Gijs van den Brink, MD, PhD, has been ...